Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006298 · ClinicalTrials.gov registry record
Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa
A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 125
- Enrollment target
NCT00006298: Completed study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00006298 is a clinical trial that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 125 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006298 has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 125 participants
- Enrollment target
Study Summary
The main goal of this study is to find out how the immune system responds to a specific type of HIV infection, known as C HIV-1, in order to develop a vaccine against this type of infection. The study involves Southern African populations. The HIV-1 virus changes rapidly and many different subtypes have been found. In South Africa, limited data have suggested Subtype C HIV-1 is the most common. This study strives to verify the most common subtype and also look at genetic differences and immune responses among newly infected individuals. Results will aid in the development of vaccines specific for certain geographical areas.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
What the finished NCT00006298 record still lists
NCT00006298 is an observational study that tracks outcomes without assigning an intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00006298 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00006298 about?
NCT00006298 is a clinical study titled "Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa". The main goal of this study is to find out how the immune system responds to a specific type of HIV infection, known as C HIV-1, in order to develop a vaccine against this type of infection. The study involves Southern African populations. The HIV-1 virus changes rapidly and many different subtypes...
What is the current status of trial NCT00006298?
This trial is currently completed. The enrollment target is 125 participants.
Who is sponsoring clinical trial NCT00006298?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve